
New research presented at Transcatheter Cardiovascular Therapeutics (TCT) 2020 showed that coronary intravascular lithotripsy (IVL) safely and effectively enabled stent delivery in severely calcified lesions.
Stent under expansion caused by coronary calcification is a significant predictor of subsequent stent thrombosis and restenosis. IVL technology emits circumferential pulsatile energy to modify calcified plaque, which can augment stent implantation. The Disrupt CAD III trial aimed to determine the safety and effectiveness of coronary IVL to optimize stent deployment in de novo stenoses involving severely calcified vessels. The non-controlled, single-arm multicenter trial was designed for U.S. regulatory approval of this technology as an addendum to coronary stenting.
The authors enrolled 384 patients with stable, unstable, or silent ischemia and severely calcified de novo coronary artery lesions undergoing percutaneous coronary intervention (PCI). Target lesions were fitted with IVL catheters and received 10 IVL pulses followed by temporary IVL balloon inflation. Treatment was repeated until full balloon expansion was achieved, with a maximum number of 80 pulses. If maximum pulses were delivered but lesion preparation remained incomplete (i.e., residual stenosis >50%), an additional IVL catheter could be implemented. Post-procedure assessments were required within 12-24 hours, and follow-up was conducted after 30 days and at 6, 12, and 24 months